Axio Joins the DataLabs CRO Partners™ Program
DataLabs, an innovative developer of Internet-based applications for clinical development, announced today that Axio Research, a contract research organization (CRO) based in Seattle, has joined the DataLabs CRO Partners Program.
Irvine, Calif. -- April 25, 2005 -- DataLabs, an innovative developer of Internet-based applications for clinical development, announced today that Axio Research, a contract research organization (CRO) based in Seattle, has joined the DataLabs CRO Partners Program.
"Axio evaluated many EDC vendors, but we ultimately joined the DataLabs CRO Partners Program because DataLabs offers technology advantages and support services at a cost that competitive vendors simply couldn't match," said Lee Hooks, Axio CEO. "We really felt that DataLabs was providing us with a tool while other EDC vendors gave the impression that they wanted to compete in our space."
"DataLabs is pleased to help Axio expand its service offerings while increasing revenue as a member of our CRO Partners Program," said Jim Langford, DataLabs president. "DataLabs understands the challenges and opportunities that CROs face, and our DataLabsXC CRO Edition suite of software is proven to conduct trials faster, easier and with fewer resources, which benefits the entire spectrum of stakeholders in clinical trials."
The DataLabs CRO Partners Program makes accelerating clinical trials easy and affordable with the DataLabsXC CRO Edition suite of software for clinical study design, electronic data capture and data management, which can be privately labeled to the CRO partner and is configurable to meet the various processes of CROs' pharmaceutical clients. Unlike traditional application service provider (ASP) models, DataLabsXC offers CROs the flexibility to adapt the software to unique specifications and conduct studies in a cost-effective manner. The program also features flexible pricing options that provide partners with a path to increased revenues. For more information, please visit www.datalabs.com/cro.html.
About Axio Research
Axio Research is a contract research organization with over 25 years of experience in providing clinical trial services to corporate, academic and government sponsors. Our current work ranges from small data entry projects for biotechnology start-ups to large, multi-center studies involving hundreds of sites and thousands of patients. We have extensive experience in the management of innovative studies for chronic and life-threatening illnesses including cancer, cystic fibrosis and other pulmonary diseases, HIV disease and cardiovascular disorders. For more information, please visit www.axioresearch.com .
About DataLabs
DataLabs is an innovative developer of Internet-based applications for clinical development that helps the biopharmaceutical industry accelerate clinical trials with proven software for study design, data capture and data management. Based on Microsoft platform technology, XML Web services and CDISC ODM standards, the DataLabsXC product suite adapts to established operating procedures and integrates easily with existing technology systems. As a result, DataLabsXC customers enjoy a low total cost of ownership and high return on investment. Major pharmaceutical companies, government entities, healthcare organizations and contract research organizations are currently realizing time and cost savings using DataLabsXC. DataLabs is based in Irvine, Calif. with East Coast offices in North Wales, Pa. For more information, please visit www.datalabs.com
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
